Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB pathways. 2020

Xiang Xu, and Hu-Nan Piao, and Fumie Aosai, and Xiao-Yu Zeng, and Jia-Hui Cheng, and Yue-Xian Cui, and Jing Li, and Juan Ma, and Hu-Ri Piao, and Xuejun Jin, and Lian-Xun Piao
Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, China.

Arctigenin, a major bioactive component of Fructus arctii, has been reported to have antidepressant-like effects. However, the mechanisms underlying these effects are still unclear. Neuroinflammation can be caused by excessive production of proinflammatory cytokines in microglia via high-mobility group box 1 (HMGB1)/TLR4/NF-κB and TNF-α/TNFR1/NF-κB signalling pathways, leading to depression. In this study, we have investigated the antidepressant mechanism of arctigenin by conducting in vitro and in vivo studies. The effects of chronic unpredictable mild stress (CUMS) on wild-type (WT) and TLR4-/- mice were examined. Antidepressant-like effects of arctigenin were tested using the CUMS-induced model of depression in WT mice. The effects of arctigenin were assessed on the HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB signalling pathways in the prefrontal cortex (PFC) of mouse brain and HMGB1- or TNF-α-stimulated primary cultured microglia. The interaction between HMGB1 and TLR4 or TNF-α and TNFR1 with or without arctigenin was examined by localized surface plasmon resonance (LSPR) and co-immunoprecipitation assays. The immobility times in the tail suspension test (TST) and forced swimming test (FST) were reduced in TLR4-/- mice, compared with WT mice. Arctigenin exhibited antidepressant-like effects. Arctigenin also inhibited microglia activation and inflammatory responses in the PFC of mouse brain. Arctigenin inhibited HMGB1 and TLR4 or TNF-α and TNFR1 interactions, and suppressed both HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB signalling pathways. Arctigenin has antidepressant-like effects by attenuating excessive microglial activation and neuroinflammation through the HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB signalling pathways. This suggests that arctigenin has potential as a new drug candidate suitable for clinical trials to treat depression.

UI MeSH Term Description Entries
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D017628 Microglia The third type of glial cell, along with astrocytes and oligodendrocytes (which together form the macroglia). Microglia vary in appearance depending on developmental stage, functional state, and anatomical location; subtype terms include ramified, perivascular, ameboid, resting, and activated. Microglia clearly are capable of phagocytosis and play an important role in a wide spectrum of neuropathologies. They have also been suggested to act in several other roles including in secretion (e.g., of cytokines and neural growth factors), in immunological processing (e.g., antigen presentation), and in central nervous system development and remodeling. Microglial Cell,Cell, Microglial,Microglial Cells,Microglias
D017705 Lignans A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Lignan,Neolignan,Neolignans
D047888 Receptors, Tumor Necrosis Factor, Type I A tumor necrosis factor receptor subtype that has specificity for TUMOR NECROSIS FACTOR ALPHA and LYMPHOTOXIN ALPHA. It is constitutively expressed in most tissues and is a key mediator of tumor necrosis factor signaling in the vast majority of cells. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM. Antigens, CD120a,CD120a Antigens,Receptors, Tumor Necrosis Factor, Member 1A,Tumor Necrosis Factor Receptor Superfamily, Member 1A,Tumor Necrosis Factor Receptor Type I,CD 120a Antigen,CD120a Antigen,TNFR p60,TNFR-I,TNFR1,TNFRSF1A (Tumor Necrosis Factor Receptor Superfamily, Member 1A),TNFRSF1A Receptor,Tumor Necrosis Factor Receptor 1A,Tumor Necrosis Factor Receptor Type 1,120a Antigen, CD,Antigen, CD 120a,Antigen, CD120a,Receptor, TNFRSF1A
D051197 Toll-Like Receptor 4 A pattern recognition receptor that interacts with LYMPHOCYTE ANTIGEN 96 and LIPOPOLYSACCHARIDES. It mediates cellular responses to GRAM-NEGATIVE BACTERIA. TLR4 Receptor,Toll-4 Receptor,Receptor, TLR4,Toll 4 Receptor,Toll Like Receptor 4
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Xiang Xu, and Hu-Nan Piao, and Fumie Aosai, and Xiao-Yu Zeng, and Jia-Hui Cheng, and Yue-Xian Cui, and Jing Li, and Juan Ma, and Hu-Ri Piao, and Xuejun Jin, and Lian-Xun Piao
August 2019, Journal of cellular physiology,
Xiang Xu, and Hu-Nan Piao, and Fumie Aosai, and Xiao-Yu Zeng, and Jia-Hui Cheng, and Yue-Xian Cui, and Jing Li, and Juan Ma, and Hu-Ri Piao, and Xuejun Jin, and Lian-Xun Piao
July 2019, Experimental and therapeutic medicine,
Xiang Xu, and Hu-Nan Piao, and Fumie Aosai, and Xiao-Yu Zeng, and Jia-Hui Cheng, and Yue-Xian Cui, and Jing Li, and Juan Ma, and Hu-Ri Piao, and Xuejun Jin, and Lian-Xun Piao
January 2022, BioMed research international,
Xiang Xu, and Hu-Nan Piao, and Fumie Aosai, and Xiao-Yu Zeng, and Jia-Hui Cheng, and Yue-Xian Cui, and Jing Li, and Juan Ma, and Hu-Ri Piao, and Xuejun Jin, and Lian-Xun Piao
January 2022, Applied bionics and biomechanics,
Xiang Xu, and Hu-Nan Piao, and Fumie Aosai, and Xiao-Yu Zeng, and Jia-Hui Cheng, and Yue-Xian Cui, and Jing Li, and Juan Ma, and Hu-Ri Piao, and Xuejun Jin, and Lian-Xun Piao
August 2022, Acta pharmacologica Sinica,
Xiang Xu, and Hu-Nan Piao, and Fumie Aosai, and Xiao-Yu Zeng, and Jia-Hui Cheng, and Yue-Xian Cui, and Jing Li, and Juan Ma, and Hu-Ri Piao, and Xuejun Jin, and Lian-Xun Piao
October 2015, European journal of pharmacology,
Xiang Xu, and Hu-Nan Piao, and Fumie Aosai, and Xiao-Yu Zeng, and Jia-Hui Cheng, and Yue-Xian Cui, and Jing Li, and Juan Ma, and Hu-Ri Piao, and Xuejun Jin, and Lian-Xun Piao
March 2019, International journal of biological macromolecules,
Xiang Xu, and Hu-Nan Piao, and Fumie Aosai, and Xiao-Yu Zeng, and Jia-Hui Cheng, and Yue-Xian Cui, and Jing Li, and Juan Ma, and Hu-Ri Piao, and Xuejun Jin, and Lian-Xun Piao
December 2015, CNS neuroscience & therapeutics,
Xiang Xu, and Hu-Nan Piao, and Fumie Aosai, and Xiao-Yu Zeng, and Jia-Hui Cheng, and Yue-Xian Cui, and Jing Li, and Juan Ma, and Hu-Ri Piao, and Xuejun Jin, and Lian-Xun Piao
January 2023, Applied bionics and biomechanics,
Xiang Xu, and Hu-Nan Piao, and Fumie Aosai, and Xiao-Yu Zeng, and Jia-Hui Cheng, and Yue-Xian Cui, and Jing Li, and Juan Ma, and Hu-Ri Piao, and Xuejun Jin, and Lian-Xun Piao
January 2024, Cell communication and signaling : CCS,
Copied contents to your clipboard!